Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
C. Moor (Rotterdam, Netherlands), M. Kimman (Maastricht, Netherlands), R. Mostard (Heerlen, Netherlands), J. Grutters (Nieuwegein, Netherlands), P. Bresser (Amsterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands). Cost-effectiveness of an online homemonitoring program in idiopathic pulmonary fibrosis. 397

Member's Comments

No comment yet.

Related content which might interest you: Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP) Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021 Year: 2021 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis Source: Eur Respir J, 51 (3) 1702508; 10.1183/13993003.02508-2017 Year: 2018 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Considerations of a warm autopsy program for patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Source: Breathe 2016; 12: 130-138 Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient Source: Eur Respir Rev 2011; 20: 114-117 Year: 2011 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 PP217 – Modeling idiopathic pulmonary fibrosis on a lung-on-chip Source: ERS Lung Science Conference 2021 Year: 2021 The epidemiologic features and the patterns of medical resource use in idiopathic pulmonary fibrosis (IPF) in Korea Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017